

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 July 2003 (10.07.2003)

PCT

(10) International Publication Number
WO 03/055516 A1(51) International Patent Classification⁷: A61K 39/395,
C07K 16/28, A61P 7/00, 9/00, G01N 33/50[GB/GB]; School of Animal and Microbial Sciences, The
University of Reading, Whiteknights House, Whiteknights,
Reading RG6 6AJ (GB).

(21) International Application Number: PCT/GB02/05730

(22) International Filing Date:
17 December 2002 (17.12.2002)(74) Agent: i.p.21 LIMITED; Norwich Research Park, Colney,
Norwich NR4 7UT (GB).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0130832.9 22 December 2001 (22.12.2001) GB(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.(71) Applicant (*for all designated States except US*): THE
UNIVERSITY OF READING [GB/GB]; Whiteknights
House, Whiteknights, Reading RG6 6AJ (GB).(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,(72) Inventor; and
(75) Inventor/Applicant (*for US only*): GIBBINS, Jonathan

[Continued on next page]

(54) Title: PECAM-1 MODULATION

A (i) PECAM-1 - +
XL Blot: anti-Tyr(P)
Blot: anti-PECAM-1

(ii) PECAM-1 XL
50s

B (i) Collagen 100µg/ml IgG control +
Collagen 100µg/ml
Light Transmission
90s

(ii) PECAM-1 XL +
Collagen 100 µg/ml
Collagen 100µg/ml
Light Transmission
90s

(57) Abstract: Activation of PECAM-1 (platelet endothelial cell adhesion molecule-1) with for example a small molecule or antibody derivative provides a new therapeutic route for modifying platelet activation and thrombus formation which has utility in the treatment or prevention of cardiovascular diseases, such as thrombosis, stroke and vascular occlusion and in the treatment or prevention of homeostasis disorders. This gives a better approach to the treatment of these conditions than existing drugs as it activates a general inhibitory mechanism rather than merely blocking one arm of the activation system. A screen for activators of PECAM-1 comprises PECAM-1, an ectodomain of PECAM-1, the cytoplasmic tail of PECAM-1, the ITIM of PECAM-1, an active site of PECAM-1, a recombinant extracellular domain of PECAM-1, or a part or derivative thereof and means for detecting activation or cross-linking or phosphorylation or tyrosine phosphorylation of PECAM-1, an ectodomain of PECAM-1, the cytoplasmic tail of PECAM-1, the IPIM of PECAM-1, an active site of PECAM-1, a recombinant extracellular domain of PECAM-1, or a part or derivative thereof.

WO 03/055516 A1

BEST AVAILABLE COPY